Skip to main content

General Rheumatology

      RheumNow’s expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All

      Dr. John Cush RheumNow

      3 months ago
      RheumNow’s expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
      The GLP-1 story has been hard to miss this year, and at ACR Convergence, it’s clear that these drugs are starting to make real waves in rheumatology. Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our patients.
      What is the #frequency of #CTD #ILD in #USA?

      Data from #Marketscan >9K & #Optum ~20k CTD-ILD Pts

      56-65 yrs, 3

      Janet Pope Janetbirdope

      3 months ago
      What is the #frequency of #CTD #ILD in #USA? Data from #Marketscan >9K & #Optum ~20k CTD-ILD Pts 56-65 yrs, 3/4 F ?under ascertained #RA-ILD - low % but #SSc-ILD approx 16% clinically relevant Same as Ont, Canada #SSc-ILD % Not rare #ACR25 @RheumNow @ACRheum Abst#0154 https://t.co/imfSyOtYpC
      High prevalence of sleep related symptoms in PsA pts!
      -Snoring 53%
      -Morning fatigue 68%
      -Obstructive Sleep Apnea in

      Aurelie Najm AurelieRheumo

      3 months ago
      High prevalence of sleep related symptoms in PsA pts! -Snoring 53% -Morning fatigue 68% -Obstructive Sleep Apnea in 50% 14% mild 19% moderate 17% severe Estimated prevalence 36% No correlation between OSA and PsA disease activity or comorbidities But small cohort! https://t.co/VKe7qcHIRm
      2 year extension data from SELECT-GCA:

      Patients in remission who remained on upadacitinib 15mg daily after 1 year had 9

      Brian Jaros, MD Dr_Brian_MD

      3 months ago
      2 year extension data from SELECT-GCA: Patients in remission who remained on upadacitinib 15mg daily after 1 year had 90% reduced risk of flare compared to those who switched to placebo Higher rates zoster, CK elevation in UPA group #ACR25 @RheumNow #ACRBest https://t.co/jf8Dh2wCBj
      The differential diagnosis for CNS vasculitis is BROAD. Keep in mind it’s mimics @RheumNow #ACR2025 https://t.co/ASWr6

      Gabriela Martinez Zayas, MD MartinezZayasMd

      3 months ago
      The differential diagnosis for CNS vasculitis is BROAD. Keep in mind it’s mimics @RheumNow #ACR2025 https://t.co/ASWr6zm5eQ
      Where do patients find informations about their RMD?

      Study of 705pts

      -80% search engines via smartphone 80.3%
      Differen

      Aurelie Najm AurelieRheumo

      3 months ago
      Where do patients find informations about their RMD? Study of 705pts -80% search engines via smartphone 80.3% Different pattern within 2 yrs of diagnosis vs. later stage: -more frequent 19% vs 8% Most users find online content -understandable 80% -apply it in daily life 68% https://t.co/9IMvpt2ffr
      Rheumatologists love AI scribes in clinic.

      The way we interact is potentially well suited, and accuracy and synthesis q

      David Liew drdavidliew

      3 months ago
      Rheumatologists love AI scribes in clinic. The way we interact is potentially well suited, and accuracy and synthesis quality is bound to improve. Is it inevitable that it will universally be standard practice for us soon? UCSF clinics #ACR25 @JYazdanyMD ABST0189 @RheumNow https://t.co/kOzfpLlvgD
      At ACR Convergence 2025, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. Studies presented at the meeting highlighted issues ranging from kidney transplant outcomes in lupus to medication disparities in rheumatoid arthritis and demographic patterns in systemic sclerosis and axial spondyloarthritis.
      PD-1+ effector memory T cells in PsA synovium are functionally active and regulate Th17 cytokines via STAT3/RORγt. Reco

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      PD-1+ effector memory T cells in PsA synovium are functionally active and regulate Th17 cytokines via STAT3/RORγt. Recombinant PD-L1 agonist significantly reduced T cell proliferation and IL-17A/F/IL-22 production highlighting checkpoint agonists as a novel therapeutic strategy https://t.co/I6eNa0j7aa
      Two Jacks, One mission 🤓

      Head on to the booth and get a chance to meet either one of them (both if you’re lucky,

      sheila RHEUMarampa

      3 months ago
      Two Jacks, One mission 🤓 Head on to the booth and get a chance to meet either one of them (both if you’re lucky, like me!) Continue tuning in for coverage of #ACR25 by the @RheumNow faculty and KOLs https://t.co/Y2pS8CpoH5
      ×